Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naive Patients with Type 2 Diabetes
Effects of Rosiglitazone/Metformin Fixed-Dose Combination Therapy and Metformin Monotherapy on Serum Vaspin, Adiponectin and IL-6 Levels in Drug-Naive Patients with Type 2 Diabetes
复制标题
DOI：
10.1055/s-0030-1265174
复制
发表时间：
2011-02-01
影响因子：
1.8
通讯作者：
Sailer, N.
中科院分区：
文献类型：
--
作者：
Kadoglou, N. P. E.;Kapelouzou, A.;Sailer, N.
目的：血管天冬氨酸、脂联素和白介素6(IL-6)是一类新的脂肪组织衍生物，称为脂肪因子，可介导胰岛素抵抗。本研究的目的是评价二甲双胍和罗格列酮对2型糖尿病(T2 DM)患者血清中这些新型脂肪因子水平的影响。方法：140例已接受饮食治疗但血糖控制不佳(HbA1c&Gt；7%)的T2 DM患者随机分为RSG+MET组(n=70)：固定剂量罗格列酮4 mg+二甲双胍500 mg。MET组(n=70)：二甲双胍单药半大剂量(1700 mg/d)。治疗6个月后分别检测体重指数(BMI)、血压(BP)、脂肪质量、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、胰岛素抵抗指数(HbA1c)、血脂、高敏C反应蛋白(HsCRP)、血管紧张素转换酶(Vaspin)、脂联素、白介素6(IL-6)。
Objective: Vaspin, adiponectin and interleukin-6 (IL-6) constitute novel adipose-tissue derivatives, known as adipokines, which mediate insulin resistance. The aim of the present study was to evaluate the effects of metformin and rosiglitazone on serum levels of those novel adipokines in drug-nave patients with type 2 diabetes mellitus (T2DM).Methods: 140 patients with T2DM, already treated with diet, but without adequate glycemic control (HbA1c>7%), were randomly assigned to: RSG+ MET group, (n=70): Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin. MET group, (n=70): Half-maximum dose of metformin monotherapy (1700 mg/day). Before and after 6-month treatment, body-mass index (BMI), blood pressure (BP), fat-mass, fasting plasma glucose (FPG), HbA1c, insulin resistance indexes (HOMA-IR, insulin), lipids, high-sensitivity CRP (hsCRP), vaspin, adiponectin, and interleukin-6 (IL-6) were measured.Results: Glucose regulation and insulin resistance were equivalently improved from baseline within both groups (p